BOCH
OVID icon

Blue Owl Capital Holdings’s Ovid Therapeutics OVID Stock Holding History

Blue Owl Capital Holdings’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.23M Buy
+1,904,666
New +$3.41M 1.14% 24
2024
Q2 		– Sell
-864,822
Closed -$2.64M – 51
2024
Q1 		$2.64M Hold
864,822
– – 0.53% 32
2023
Q4 		$2.78M Buy
+864,822
New +$2.96M 0.67% 25

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Blue Owl Capital Holdings's OVID Position: Q1 2026 in Review

Blue Owl Capital Holdings opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 1,904,666 shares worth $4.23M. The stake represents 1.14% of the portfolio and ranks #24 among its holdings. This is a return to the name: Blue Owl Capital Holdings previously reported a position in OVID as recently as Q1 2024.

Blue Owl Capital Holdings first reported a position in OVID in Q4 2023 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Blue Owl Capital Holdings held 1,904,666 shares of Ovid Therapeutics worth $4.23M as of Q1 2026.
  • Ovid Therapeutics was a new Blue Owl Capital Holdings position in Q1 2026.
  • Ovid Therapeutics made up 1.14% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #24 holding.
  • Blue Owl Capital Holdings first reported a position in Ovid Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.